The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients

被引：0
|
作者：
Anne Flint
Christoph Kapitza
Charlotte Hindsberger
Milan Zdravkovic
机构：
[1] Novo Nordisk A/S,
[2] Novo Nordisk A/S,undefined
[3] PROFIL Institut für Stoffwechselforschung GmbH,undefined
来源：
Advances in Therapy | 2011年 / 28卷
关键词：
exenatide; gastric emptying; incretin; insulin; type 2 diabetes mellitus;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：213 / 226
页数：13
相关论文
共 50 条
  • [21] Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes
    Ryan, Gina J.
    Hardy, Yolanda
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2011, 36 (03) : 260 - 274
  • [22] The human glucagon-like peptide-1 (GLP-1) receptor
    Dillon, JS
    Wheeler, MB
    Leng, XH
    Ligon, BB
    Boyd, AE
    PHYSIOLOGY AND PATHOPHYSIOLOGY OF THE ISLETS OF LANGERHANS, 1997, 426 : 113 - 119
  • [23] The once-daily human GLP-1 analog-liraglutide reduces systolic blood pressure in patients with type 2 diabetes
    Colagiuri, Steven
    Frid, Anders
    Zdravkovic, Milan
    Le-Thi, Tu Duyen
    Vaag, Allan
    DIABETES, 2008, 57 : A164 - A165
  • [24] Glucagon-like peptide-1 (GLP-1) in obese subjects with and without type 2 diabetes
    Rotella, CM
    Ognibene, A
    Cremasco, F
    Bardini, G
    Mencucci, A
    Pierazzuoli, E
    Ciani, S
    Messeri, G
    Mannucci, E
    DIABETES, 2000, 49 : A1 - A1
  • [25] Treatment of type 1 diabetic patients with residual beta cell function with the once-daily glucagon-like peptide-1 analogue liraglutide
    Kielgast, U.
    Holst, J. J.
    Madsbad, S.
    DIABETOLOGIA, 2010, 53
  • [26] Liraglutide: a once-daily GLP-1 analogue for the treatment of Type 2 diabetes mellitus
    Vilsboll, Tina
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (02) : 231 - 237
  • [27] Pharmacokinetic modelling of the once-daily human glucagon-like peptide-1 analogue, liraglutide, in healthy volunteers and comparison to exenatide
    Jonker, D. M.
    Watson, E.
    Toft, A. D.
    Kristensen, P.
    Knudsen, L. B.
    Ingwersen, S. H.
    DIABETOLOGIA, 2007, 50 : S351 - S352
  • [28] Impaired postprandial release of glucagon-like peptide-1 in patients with Type 2 diabetes
    Lindqvist, J
    Pigon, J
    Holst, JJ
    Efendic, S
    DIABETOLOGIA, 1998, 41 : A184 - A184
  • [29] The glucagon-like peptide-1 receptor agonist, liraglutide, does not suppress postprandial cholecystokinin in patients with type 1 diabetes
    Johansen, N. J.
    Dejgaard, T. F.
    Frandsen, C. S.
    Lund, A.
    Knop, F. K.
    Rehfeld, J. F.
    Madsbad, S.
    Andersen, H. U.
    DIABETOLOGIA, 2019, 62 : S377 - S378
  • [30] Preserved Inhibitory Effect of Glucagon-Like Peptide-1 (GLP-1) on Glucagon Secretion in Type 2 Diabetes Mellitus
    Hare, Kristine J.
    Knop, Filip K.
    Asmar, Meena
    Larsen, Steen
    Madsbad, Sten
    Holst, Jens J.
    Vilsboll, Tina
    DIABETES, 2009, 58 : A372 - A372
12345